Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Revises Price Target Higher From $5.50 to $7.00

SAN FRANCISCO, CA--(Marketwired - Sep 24, 2014) - Vista Partners announced today that it has updated coverage on Soligenix, Inc. (OTCBB: SNGX), based in Princeton, New Jersey, and revised its twelve-month price target higher from $5.50 to $7.00. Ross Silver, Principal Analyst at Vista Partners, stated, "The Company boasts a diverse pipeline with ten prospective drug candidates, including a Phase 3 ready asset slated to enter the clinic in early 2015. The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. The Company has been awarded numerous government grants and entered into strategic agreements with two companies, Intrexon (~$1.9B mkt cap.) and SciClone (~$360M mkt cap). The main financial contributor has been the U.S. government. To date, the Company has been awarded approximately $40M mainly through BARDA, NIH and FDA grants/contracts. On top of the $7.1M financing completed in 2013, the Company has up to approximately $57 million in active government contracts and grant funding still available to support its associated research programs through 2018. The Company is in the process of petitioning and filling applications for a number of additional grants for further support of its programs with various funding agencies."

To download a FREE copy of the Soligenix, Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report. 

About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista's mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes. 

Please follow us on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more.

Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.